Abstract
Since the advent of COVID-19 as a pandemic, multiple therapeutic options
have been looked into as possible options for the management of COVID-19
disease. Remdesivir, a broad-spectrum anti-viral, has since been given
Emergency Use Authorization by the US Food and Drug Agency (FDA). While
cohort studies have shown benefit in the use of Remdesivir, the only
Randomized Controlled Trial showed no statistically significant clinical
benefit, and the other results from a trial by the NIH has only shown
some benefit in reducing hospital admission in early results prior to
peer review. In this scenario, with data lacking, is it justified for
Remdesivir to be given Emergency Use Authorization?